关键词：医药；治疗技术；激素治疗；前列腺癌
摘 要：During the past 12 months, we have received IRB approval from Mount Sinai School of Medicine, the James P. Peters VA Medical Center IRBs, and the Department of Defense. We have also held three focus groups with prostate cancer patients undergoing hormone therapy and multiple research team meetings were held to discuss focus group results, software development, and study protocol. We are currently integrating feedback from the final focus group into the vasomotor symptom intervention (VSI) and plan to run a final focus group to test the usability of the application. Our progress over the previous project period has led us to refine the methodology and software development, and this will allow us to begin the intervention phase during Y2 of the award.